SEC Filing Details

Our enduring purpose: to fundamentally improve the lives of patients with serious diseases in ways never before possible.

SEC Filing Details

Document Details

Form
Filing Date
Oct 2, 2019
Document Date
Oct 1, 2019
Form Description
Initial filing by director officer or owner of more than ten percent.
Filing Group
3,4,5
Company
Five Prime Therapeutics
Issuer
FIVE PRIME THERAPEUTICS, INC.
Filer
BIOTECHNOLOGY VALUE FUND II LP